EHR

Patient Engagement Solutions Market to Grow at a Robust CAGR of 21.25%, Crossing USD 229.5 Billion by 2035 | Vantage Market Research

NEW YORK  , Jan. 20, 2026 /PRNewswire/ -- The Global Patient Engagement Solutions Market is undergoing a profound transformation as healthcare systems worldwide...

Patient Engagement Solutions Market to Grow at a Robust CAGR of 21.25%, Crossing USD 229.5 Billion by 2035 | Vantage Market Research

NEW YORK  , Jan. 20, 2026 /PRNewswire/ -- The Global Patient Engagement Solutions Market is undergoing a profound transformation as healthcare systems worldwide...

Brainomix e-Lung AI Imaging Technology Selected as Co-Primary Endpoint in Boehringer Ingelheim Phase 3 Clinical Trial in Pulmonary Fibrosis

The DROP-FPF trial is the first Phase 3 trial in interstitial lung disease (ILD) to use automated, quantitative high-resolution CT scan...

Brainomix e-Lung AI Imaging Technology Selected as Co-Primary Endpoint in Boehringer Ingelheim Phase 3 Clinical Trial in Pulmonary Fibrosis

The DROP-FPF trial is the first Phase 3 trial in interstitial lung disease (ILD) to use automated, quantitative high-resolution CT scan...

Brainomix e-Lung AI Imaging Technology Selected as Co-Primary Endpoint in Boehringer Ingelheim Phase 3 Clinical Trial in Pulmonary Fibrosis

The DROP-FPF trial is the first Phase 3 trial in interstitial lung disease (ILD) to use automated, quantitative high-resolution CT scan...

Black Book Research: Rural Hospital Survey Finds Health IT Still Too Often “Urban-First,” Driving Added Burden for Lean Rural Teams

205 rural small and Critical Access Hospital IT, clinical, and financial users cite repackaged health-system solutions, misaligned implementation models, and...

Ambulatory EHR Excellence 2026: Top Vendors Recognized for Breakthrough Innovation and Specialty User Satisfaction in Black Book 2026 Surveys

ModMed, Epic, NextGen Healthcare, Netsmart, athenahealth, and Specialty Category Innovators Lead Black Book's 2026 Ambulatory EHR Rankings NEW YORK CITY,...

GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers

GT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary, unaudited cash balance of approximately...

error: Content is protected !!